IP Library Granted Patent US 10,463,283
Granted Patent B2
US 10,463,283 · App. 14/214,175 · Granted Nov 5, 2019

Systems and methods of multispectral blood measurement

Inventors: Elad Ferber (Woodside, CA); Pierre-Jean Cobut (Menlo Park, CA)
Assignee: Spry Health, Inc.
A61B5/14532A61B5/0022A61B5/0205A61B5/1455A61B5/14535A61B5/14539G06F19/00G16H40/67A61B5/681A61B5/721A61B5/743A61B2560/045
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,463,283
App. No.
14/214,175
Filed
Mar 14, 2014
Granted
Nov 5, 2019
Kind
B2
Art Unit
3791
USPC
600/315
Abstract

An exemplary system comprises an energy transmitter, an energy receiver, and an analyzer. The energy transmitter may project energy at a first wavelength and a second wavelength into tissue of a user, the first wavelength and the second wavelength being associated with at least one nutrient of a set of nutrients in blood of the user. The energy receiver may generate a composite signal based on a fraction of the energy at the first wavelength and the second wavelength, the fraction of the energy being received through the tissue of the user. The analyzer may separate the composite signal into a first signal corresponding to the first wavelength and a second signal corresponding to the second wavelength, and detect, in the blood of the user, a concentration of the at least one nutrient of the set of nutrients based on the first signal and the second signal.

Claims (42)

1. A system comprising:

a flexible wrist band;

a plurality of light emitting diodes secured to the flexible wrist band, a first of the plurality of light emitting diodes configured to project energy at a first wavelength into tissue of a wearer and a second of the plurality of light emitting diodes configured to project energy at a second wavelength into the tissue of the wearer, the first wavelength and the second wavelength being associated with different analyte concentrations in blood of the wearer;

at least one photo detector secured to the flexible wrist band, the at least one photo detector being adjacent to the plurality of light emitting diodes and configured to generate a composite signal based on a fraction of the energy at the first wavelength and the second wavelength, the fraction of the energy being reflected by the tissue of the wearer; and

a processor configured to:

separate the composite signal into a first signal corresponding to the first wavelength and a second signal corresponding to the second wavelength, and detect, in the blood of the wearer, a first analyte concentration measurement of a first analyte and a second analyte concentration measurement of a second analyte within the blood of the wearer based on the first signal and the second signal, respectively;

apply a Kalman filter to the first analyte concentration measurement and the second analyte concentration measurement;

compare a result of the application of the Kalman filter to the first analyte concentration measurement and the second analyte concentration measurement with at least one threshold associated with motion of the wearer to determine if at least the first analyte concentration measurement or the second analyte concentration measurement is abnormal as being influenced by the motion of the wearer;

if the first analyte concentration measurement and the second analyte concentration measurement are abnormal based on the comparison, remove abnormal measurements associated with the motion of the wearer; and

if the first analyte concentration measurement and the second analyte concentration measurement are not determined to be abnormal based on the comparison, obtain a first analyte concentration of the first analyte and a second analyte concentration of the second analyte based at least on an assessment of the first analyte concentration measurement and a second analyte concentration measurement in a frequency domain.

2. The system of claim 1 , wherein the processor is further configured to determine a set of blood metrics based on the first analyte concentration and the second analyte concentration.

3. The system of claim 2 , further comprising a display coupled to the processor, the processor configured to display a user interface on the display, the user interface including at least some of the set of blood metrics.

4. The system of claim 2 , wherein the processor is further configured to compare a blood metric of the set of blood metrics to a threshold and to generate an alert if the blood metric exceeds the threshold.

5. The system of claim 2 , wherein the set of blood metrics comprises a blood glucose concentration.

6. The system of claim 1 , wherein the processor is further configured to determine a first AC component and a first DC component of the first signal and to determine a second AC component and a second DC component of the second signal, wherein the first analyte concentration measurement is detected based on the first AC component and the first DC component, and the second analyte concentration measurement is detected based on the second AC component and the second DC component.

7. The system of claim 1 , wherein the first analyte concentration measurement is a measurement of concentration of hemoglobin, triglyceride, bilirubin, protein, albumin, cortisol, or electrolyte.

8. A method comprising:

projecting a first wavelength of energy into tissue of a user;

projecting a second wavelength of energy into the tissue of the user, the first wavelength and the second wavelength being associated with different analyte concentrations in blood of the user;

receiving a fraction of the energy at the first and second wavelengths, the fraction of the energy being reflected by the tissue of the user;

generating a composite signal based on the fraction of the energy at the first wavelength and the second wavelength, the fraction of the energy being reflected by the tissue of the user;

separating, by a processor, the composite signal into a first signal corresponding to the first wavelength and a second signal corresponding to the second wavelength;

detecting, by a processor, a first analyte concentration measurement of a first analyte in the blood of the user based on the first wavelength and a second analyte concentration measurement of a second analyte in the blood of the wearer based on the second wavelength;

applying, by a processor, a Kalman filter to the first analyte concentration measurement and the second analyte concentration measurement;

comparing, by a processor, a result of the application of the Kalman filter to the first analyte concentration measurement and the second analyte concentration measurement with at least one threshold associated with motion of the wearer to determine if the at least the first analyte concentration measurement or the second analyte concentration measurement is abnormal as being influenced by the movement of the user;

if the first analyte concentration measurement and the second analyte concentration measurement are abnormal based on the comparison, remove abnormal measurements associated with movement by the user; and

if the first analyte concentration measurement and the second analyte concentration measurement are not determined to be abnormal based on the comparison, obtain a first analyte concentration of the first analyte and a second analyte concentration of the second analyte based at least on an assessment of the first analyte concentration measurement and the second concentration measurement in a frequency domain.

9. The method of claim 8 , further comprising displaying, on a display communicatively coupled to the processor the first analyte concentration measurement.

10. The method of claim 8 , further comprising comparing the first analyte concentration to a threshold and generating an alert if the first analyte concentration exceeds the threshold.

11. The method of claim 8 , wherein the first analyte concentration comprises a blood glucose concentration.

12. The method of claim 8 , further comprising determining a first AC component and a first DC component of the first signal and determining a second AC component and a second DC component of the second signal, wherein the first analyte concentration measurement is detected based on the first AC component and the first DC component, and the second analyte concentration measurement is detected based on the second AC component and the second DC component.

13. The method of claim 8 , wherein the first analyte concentration measurement is a measurement of concentration of hemoglobin, triglyceride, bilirubin, protein, albumin, cortisol, or electrolyte.

14. A system comprising:

a flexible wrist band;

a plurality of light emitting diodes secured to the flexible wrist band, a first of the plurality of light emitting diodes configured to project energy at a first wavelength into tissue of a wearer and a second of the plurality of light emitting diodes configured to project energy at a second wavelength into the tissue of the wearer, the first wavelength and the second wavelength being associated with different analyte concentrations in blood of the wearer, the different analyte concentrations being at least two selected from a set of components comprising hemoglobin, triglycerides, bilirubin, protein, albumin, blood pH, Hematocrit, cortisol, and electrolytes;

at least one photo detector secured to the flexible wrist band, the at least one photo detector being adjacent to the plurality of light emitting diodes and configured to generate a composite signal based on a fraction of the energy at the first wavelength and the second wavelength, the fraction of the energy being reflected by the tissue of the wearer; and

a processor configured to:

separate the composite signal into a first signal corresponding to the first wavelength and a second signal corresponding to the second wavelength, and to detect, in the blood of the wearer, a first analyte concentration measurement of a first analyte and a second analyte concentration measurement of a second analyte within the blood of the wearer based on the first signal and the second signal, respectively;

apply a Kalman filter to the first analyte concentration measurement and the second analyte concentration measurement;

compare a result of the application of the Kalman filter to the first analyte concentration measurement and the second analyte concentration measurement with at least one threshold associated with motion of the wearer to determine if at least the first analyte concentration measurement or the second analyte concentration measurement is abnormal as being influenced by the motion of the wearer;

if the first analyte concentration measurement and the second analyte concentration measurement are abnormal based on the comparison, remove abnormal measurements associated with movement by the wearer; and

if the first analyte concentration measurement and the second analyte concentration measurement are not determined to be abnormal based on the comparison, obtain a first analyte concentration of the first analyte and a second analyte concentration of the second analyte based at least on an assessment of the first analyte concentration measurement and the second analyte concentration measurement in a frequency domain.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2021
From: ITAMAR MEDICAL, LTD.
To: ITAMAR MEDICAL SPRY 2021, LIMITED PARTNERSHIP
Reel/Frame 057326/0340 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2021
From: SPRY HEALTH, INC.
To: ITAMAR MEDICAL LTD.
Reel/Frame 057260/0358 →
CHANGE OF NAME Recorded Aug 19, 2021
From: ECHO LABS, INC.
To: SPRY HEALTH, INC.
Reel/Frame 057246/0810 →
CHANGE OF NAME Recorded Jul 17, 2017
From: ECHO LABS, INC.
To: SPRY HEALTH, INC.
Reel/Frame 043216/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2014
From: FERBER, ELAD; COBUT, PIERRE-JEAN
To: ECHO LABS, INC.
Reel/Frame 033643/0028 →
Continuity (3)
Provisional Application 61785417 · Mar 14, 2013
Provisional Application 61947357 · Mar 3, 2014
Related Publication 20140316226A1 · Oct 23, 2014
Cited By (40)
US 12,210,381 US 12,222,758 US 12,222,759 US 12,228,968 US 12,235,679 US 12,306,669 US 12,332,688 US 12,332,689 US 12,346,160 US 12,376,802 US 12,393,227 US 12,393,228 US 12,393,229 US 12,399,530 US 12,399,531 US 12,422,889 US 12,429,908 US 12,429,909 US 12,429,910 US 12,429,911 US 12,436,566 US 12,443,228 US 12,443,229 US 12,443,230 US 12,443,231 US 12,449,843 US 12,449,844 US 12,449,845 US 12,449,846 US 12,449,847 US 12,449,848 US 12,449,849 US 12,461,560 US 12,461,561 US 12,468,342 US 12,493,321 US 12,498,756 US 12,530,050 US 12,564,326 US 12,653,461